BI 836845

DRUG4 trials

Sponsors

Boehringer Ingelheim

Conditions

NeoplasmsProstatic Neoplasms, Castration-Resistant

Phase 1

Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types

CompletedNCT01317420

Boehringer IngelheimNeoplasms

Start: 2011-04-13End: 2016-02-15Updated: 2025-07-11

Phase I Trial of BI 836845 for Various Solid Cancer

CompletedNCT01403974

Boehringer IngelheimNeoplasms

Start: 2011-07-19End: 2015-12-23Updated: 2025-07-25

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

CompletedNCT02123823

Boehringer IngelheimNeoplasms

Start: 2014-05-15End: 2021-12-14Updated: 2025-07-15

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

CompletedNCT02204072

Boehringer IngelheimProstatic Neoplasms, Castration-Resistant

Start: 2014-11-11End: 2023-06-01Updated: 2025-07-15

Related Papers

Artificial intelligence and radiomics biomarkers for treatment response prediction in advanced HER2-negative breast cancer.

2025-09-03

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.

2021-01-1519 citations

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.

2020-03-1231 citations

Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

Journal of Clinical Oncology2019-05-205 citations

Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results.

Journal of Clinical Oncology2016-05-204 citations

Phase I dose escalation study of 3-weekly BI 836845, a fully human, affinity optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid tumors.

Journal of Clinical Oncology2014-05-205 citations

A phase I dose escalation study of weekly BI 836845, a fully human, affinity-optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid cancers.

Journal of Clinical Oncology2014-05-203 citations